Researchers are reporting development of a new method that could improve the safety and efficacy of bone marrow transplants used for treating advanced blood cancers. In the new study using mouse models of lymphoma (a type of blood cancer), the researchers genetically engineered immune cells (T cells) from a donor in a way that made the cells less likely to cause graft-versus-host disease (GVHD). GVHD is a potentially deadly complication in which donor white blood cells attack healthy tissues in the recipient. The study, published in Nature Medicine, was partly funded by NHLBI.
Media Coverage
|
The American Journal of Managed Care